Hepatology
Fatty Liver Disease (MASLD)
Modern, evidence-based evaluation and treatment of MASLD, MASH, and metabolic liver disease — with Dr. Azaan Ramani, DO at Texas Digestive Disease Consultants and Baylor Scott & White Health in DFW.
Fatty liver disease — now formally renamed MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) — affects roughly 1 in 4 American adults and is the leading cause of chronic liver disease in the United States. The good news: early-stage MASLD is often reversible.
What Is MASLD?
MASLD is the accumulation of fat in liver cells in the setting of metabolic risk factors — obesity, type 2 diabetes, hypertension, dyslipidemia. The term replaced "NAFLD" (non-alcoholic fatty liver disease) in 2023 to better reflect the metabolic origin of the disease and reduce stigma.
The disease spectrum includes:
- Simple steatosis: fat in the liver without significant inflammation
- MASH (Metabolic dysfunction-Associated Steatohepatitis): fat plus inflammation and liver cell injury — the active progressive form
- Fibrosis: scar tissue formation in response to ongoing injury (stages F1–F3)
- Cirrhosis (F4): advanced scarring with potential complications
- Hepatocellular carcinoma (HCC): a known long-term risk in MASLD-related cirrhosis
Symptoms and Diagnosis
Most patients with early MASLD have no symptoms. The disease is typically discovered through:
- Mildly elevated ALT and AST on routine labs
- Incidental finding of fatty liver on abdominal imaging (ultrasound, CT, MRI)
- Workup for unexplained metabolic risk factors
When MASLD is suspected, evaluation includes:
- FibroScan: a non-invasive ultrasound-based test that quantifies liver stiffness (fibrosis) and fat content
- FIB-4 and NAFLD Fibrosis Score: simple lab-based scores to risk-stratify
- Viral hepatitis panel, autoimmune labs, iron studies, and ceruloplasmin to rule out other causes
- MR Elastography (MRE): gold-standard non-invasive fibrosis assessment in select cases
- Liver biopsy: reserved for cases with diagnostic uncertainty or high-risk features
Treatment
Lifestyle (the foundation)
- 7–10% body weight loss reduces liver fat, inflammation, and fibrosis — the single most effective intervention
- Mediterranean diet: emphasizes vegetables, legumes, whole grains, olive oil, fish, and nuts
- Reduce added sugar and ultra-processed foods
- Limit alcohol — even modest intake amplifies metabolic liver injury
- Aerobic and resistance exercise — both have independent benefits on liver fat
Pharmacotherapy
- Resmetirom (Rezdiffra) — first FDA-approved therapy for MASH with significant fibrosis, approved 2024
- GLP-1 receptor agonists (semaglutide, tirzepatide) — strong emerging evidence for MASH improvement
- Pioglitazone and Vitamin E — used selectively in non-diabetic MASH
- Statins — safe and beneficial for cardiovascular risk in MASLD
Comorbid disease management
Aggressive treatment of type 2 diabetes, dyslipidemia, hypertension, and obesity is integral to MASLD care.
Surveillance and Long-Term Care
Patients with MASLD-related cirrhosis require:
- HCC surveillance with abdominal ultrasound (and AFP) every 6 months
- Variceal screening via upper endoscopy
- Cardiovascular risk management — leading cause of death in MASLD patients
Fatty Liver Disease: Common Questions
Can fatty liver disease be reversed?
Yes — early MASLD is often reversible with 7–10% body weight loss, Mediterranean-style diet, exercise, and treatment of metabolic risk factors. Advanced fibrosis can sometimes regress. Cirrhosis is generally not fully reversible but can be stabilized.
What's the difference between NAFLD and MASLD?
MASLD is the new 2023 name for NAFLD. The change emphasizes the metabolic origin of the disease and reduces stigma. Same clinical entity, updated nomenclature.
Do GLP-1 medications help fatty liver disease?
Yes — multiple trials show semaglutide and tirzepatide significantly improve MASH and reduce liver fat. GLP-1 medications are increasingly used in MASLD patients with concurrent obesity or type 2 diabetes.
What's a FibroScan and is it accurate?
FibroScan is a 10-minute non-invasive test that measures liver stiffness and fat content. It accurately stratifies fibrosis risk and often avoids the need for liver biopsy.
What does an elevated ALT mean?
ALT rises when liver cells are injured. Most common causes of mild persistent elevation: MASLD, alcohol, medications, and viral hepatitis. Persistent elevation warrants a hepatology workup.
Is fatty liver disease serious?
It can be. While simple fatty liver is often benign, MASH with significant fibrosis can progress to cirrhosis, liver failure, and HCC. MASLD is also a major cardiovascular risk factor — making early evaluation worthwhile.
Ready to schedule a consultation?
Dr. Ramani sees patients across the Dallas–Fort Worth area. Send a message and his team will be in touch.
Connect with Dr. Ramani →